ClinicalTrials.Veeva

Menu

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

Virginia Commonwealth University (VCU) logo

Virginia Commonwealth University (VCU)

Status and phase

Enrolling
Phase 2

Conditions

Breast Cancer

Treatments

Drug: Accelerated partial breast irradiation

Study type

Interventional

Funder types

Other

Identifiers

NCT06185205
HM20027787 (Other Identifier)
MCC-22-19248

Details and patient eligibility

About

The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.

Full description

This phase 2, single-arm prospective study has been designed to determine the safety of delivering accelerated partial breast irradiation (APBI) with a multicatheter interstitial implant in a short course over 1.5 days

Enrollment

120 estimated patients

Sex

Female

Ages

45 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female

  • New diagnosis of ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma per histologic evaluation

  • Age 45-79 at diagnosis

  • Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist.

  • T stage of Tis, T1, or T2.

  • T2 tumors must be ≤3 cm in maximum diameter

  • If the tumor is human epidermal growth factor receptor 2 (HER2)-positive, the patient must receive HER2-directed therapy.

  • For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy alone or axillary dissection [with a minimum of 6 axillary nodes removed]) and the axillary node[s] must be pathologically negative.

  • Note: N0(i+) is not an exclusion criterion.

  • Note: Patients meeting all of the following criteria are not required to undergo the axillary staging procedure:

    • ≥70 years of age
    • estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
    • G1-2
    • Tumor ≤2 cm in size
    • Agrees to comply with aromatase inhibitor recommendation
  • Ability to understand and the willingness to sign a written informed consent document in English

Exclusion criteria

  • Pregnant or breastfeeding
  • Active collagen-vascular disease
  • Paget's disease of the breast
  • History of DCIS or invasive breast cancer prior to the current diagnosis
  • Prior breast or thoracic radiation therapy (RT) for any condition
  • Multicentric carcinoma (DCIS or invasive)
  • Synchronous bilateral invasive or non-invasive breast cancer
  • Surgical margins that cannot be microscopically assessed or that are positive
  • Excision cavity that cannot be clearly delineated per the treating investigator
  • Any of the dosimetric treatment criteria defined in Section 6.1 have not been met. Patients who become ineligible due to inability to meet dosimetric criteria should not receive treatment as - defined in this protocol and will come off the study. Any subsequent adjuvant radiation will be delivered at the discretion of the treating physician
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

120 participants in 1 patient group

Accelerated Partial Breast Irradiation (APBI)
Experimental group
Description:
7.5 gray (Gy) × 3 fractions via multicatheter brachytherapy
Treatment:
Drug: Accelerated partial breast irradiation

Trial contacts and locations

1

Loading...

Central trial contact

Massey IIT Research Operations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems